The #BHF Manchester Heart & Lung CMR research unit is nearly up and running! We couldn’t be prouder of Dr Miller and the research team for realising this ambition 👏🏼NW Hearts British Heart Foundation MFT NHS

Outstanding talk! Heart_SCCT Dr Andrew D. Choi Dr. Todd C. Villines Ron Blankstein John Lesser Kavitha Chinnaiyan, MD Marcio S Bittencourt Khurram Nasir Mouaz Al-Mallah, M.D MSc Dr. Purvi Parwani Juan Lopez-Mattei, MD Minneapolis Heart Institute Foundation Abbott Northwestern David Caye

Love this #cardioonc #WhyCMR Erik Schelbert

Congratulations Maan Malahfji. Another investigation demonstrating the utility of #whycmr in valvular heart disease. @AlpanaSenapati Michael Reardon M Quinones MD, MACC WilliamZoghbi Houston Methodist CV Myocardial Scar and Mortality in Chronic Aortic Regurgitation ahajournals.org/doi/10.1161/JA…

Seth Uretsky Dipan J. Shah, MD DebbieKwonMD Society for Cardiovascular Magnetic Resonance Erik Schelbert Imaging right after Gd injection is best. Chronic, organized thrombus can enhance over time. Delayed imaging can make the thrombus appear smaller, or can result in a missed diagnosis. Some people say “thrombus doesn’t enhance.” Don’t believe them! This case proves otherwise.

Dr Pfeffer Brigham and Women's Hospital makes the case that #TOPCAT data from Russia and Georgia should be censored #FDA CV & Renal Drugs Advisory Committee on Spironolactone and HFpEF Blood levels of Spironolactone metabolites suggest false reporting John Mandrola, MD

Best holiday card from a patient so far

Prognosis in secondary MR is influenced by the severity of MR and by the extent of myocardial scar, both assessed by #valvecmr. New role for #whyCMR in the selection of patients for MitraClip? Congratulations to Bhupendar Tayal new pub in JACC Journals jacc.org/doi/10.1016/j.…

Proud to be involved with this work on septal SCAD seeing through the lens of #whyCMR led by Minneapolis Heart Institute Foundation Scott Sharkey, Timothy Henry and Jacqueline Saw. academic.oup.com/ehjacc/advance…

Please share with your colleagues and #ACCFIT our 1-year Advanced CV Imaging Fellowship in CT and MRI Minneapolis Heart Institute Foundation. 2022 application deadline is Feb 15th! Pls DM for any questions. American College of Cardiology Heart_SCCT Society for Cardiovascular Magnetic Resonance ACC Minnesota Chapter bit.ly/3tcsQQC

Society for Cardiovascular Magnetic Resonance ASNC Society American College of Radiology American College of Cardiology can someone please explain to how this can be right? References outdated 2014 ACR AUC and feedback goes to National Decision Support Company. #cardiotwitter Danielle Belardo, MD Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 David J. Cohen, MD, MSc Less-Is-More Cardiologist C Bucciarelli-Ducci John Mandrola, MD Jonathan Reiner

1/7 Here is a #tweetorial on our approach to evaluating #mitralregurgitation using #WhyCMR at #MorristownCards Society for Cardiovascular Magnetic Resonance Jordan Safirstein MD Linda Gillam MD, MPH, MACC, FASE, FAHA, FESC Matthew W Martinez Lillian Aldaia, MD, FACC Philippe Genereux

Thank you, #scmr for giving me the honour of being SCMR gold medalist. There is no peer group that would mean more to me. Let’s get CMR to the next level! #whycmr #SCMR2021

Congratulations to the new Society for Cardiovascular Magnetic Resonance president Dr. @HeartDocSubha! Pic from #SCMR2017 when Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 made the introduction virtually. Your contributions to the #whyCMR inspire so many womeninCMR! So excited for this year, working under your leadership🥂 #SCMR2021

Non-invasive characterization of pleural and pericardial effusions using T1 mapping by magnetic resonance imaging doi.org/10.1093/ehjci/… #EHJCVI #EACVI #EACVI #EACVIPresident European Society of Cardiology Journals

T1 values of pleural and pericardial effusions help distinguish transudates vs exudates - simple clinical #whyCMR tool can ⬇️ need for invasive sampling Society for Cardiovascular Magnetic Resonance Juan Lopez-Mattei, MD C Bucciarelli-Ducci Steffen Petersen Manish Motwani James moon Stefania Rosmini EACVI President

And pericardial blood (lowest T1) completely characteristic! T1 mapping for fluid characterisation genuinely useful!

In a double-blind, randomized phase 2 #clinicaltrial, treatment of patients with #heartfailure with preserved ejection fraction (HFpEF) with the oral anti-fibrotic agent pirfenidone reduced myocardial fibrosis. #NMEDClinical NW Hearts The University of Manchester nature.com/articles/s4159…

Myocardial fibrosis is reduced by pirfenidone in patients with HFpEF. Thank you to everyone who helped in the PIROUETTE trial! Erik Schelbert Simon Williams Colin C fozia ahmed Theresa McDonagh Liverpool Clinical Trials Centre (LCTC) National Institute for Health and Care Research The University of Manchester @MCRImaging MFT Research and Innovation

#whycmr myocardial ECV in HFpEF can be reduced over 1 year with anti-fibrotic agent pifenidone. Promising! Erik Schelbert